Sugi Predict

Sugi Predict / Compounds / SCHEMBL3546343

SCHEMBL3546343

SCHEMBL3546343

COC(=O)[C@H]1C=CCN1C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 2/20 0.39
▸ NR1H2 P55055 1/20 0.37
▸ NR1H3 Q13133 1/20 0.37
▸ NPC1 O15118 1/20 0.36
▸ PREP P48147 1/20 0.36
▸ PDE4B Q07343 1/20 0.36
▸ ACE P12821 1/20 0.36
▸ CTSK P43235 1/20 0.36
▸ LMNA P02545 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ NFKB1 P19838 1/20 0.35
▸ NFKB2 Q00653 1/20 0.35
▸ RELA Q04206 1/20 0.35
▸ CYP1A2 P05177 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ CHRM2 P08172 1/20 0.34
▸ CHRM1 P11229 1/20 0.34
▸ CHRM3 P20309 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2559556 1.00 PTPN1 (0.39) PTPN1NR1H2NR1H3NPC1PREP
SCHEMBL3546340 1.00 PTPN1 (0.39) PTPN1NR1H2NR1H3NPC1PREP
SCHEMBL31375026 0.90 PREP (0.38) NR1H2NPC1PREPACECTSK
SCHEMBL10137609 0.90 PREP (0.38) NR1H2NPC1PREPACECTSK
SCHEMBL28773549 0.85 NR1H2 (0.38) PTPN1NR1H2NR1H3NPC1PDE4B
SCHEMBL25175295 0.84 ACE (0.47) NR1H2NPC1PREPACECTSK
SCHEMBL629586 0.84 ACE (0.47) NR1H2NPC1PREPACECTSK
SCHEMBL629585 0.84 ACE (0.47) NR1H2NPC1PREPACECTSK
SCHEMBL13519523 0.84 NFKB1 (0.41) PREPACECTSKLMNANPSR1
SCHEMBL6789639 0.84 NFKB1 (0.41) PREPACECTSKLMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243187-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-07-31 — — US disclosed
EP-4551569-A1 ANTI-VIRAL COMPOUNDS Aligos Therapeutics, Inc. (US) 2025-05-14 — — EP disclosed
US-20240390340-A1 PYRROLIDINE KRAS INHIBITORS INCYTE CORP (US) 2024-11-28 — — US disclosed
US-20240327434-A1 FUSED TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2024-10-03 — — US disclosed
EP-4366831-A1 ANTI-VIRAL COMPOUNDS Aligos Therapeutics, Inc. (US) 2024-05-15 — — EP disclosed
EP-4361157-A1 FUSED TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) 2024-05-01 — — EP disclosed
US-20240109871-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-04-04 — — US disclosed
US-20240018126-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-01-18 — — US disclosed
US-11851422-B2 Anti-viral compounds ALIGOS THERAPEUTICS, INC. 2023-12-26 — — US disclosed
US-20230093249-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-03-23 — — US disclosed
WO-2023283256-A1 ANTI-VIRAL COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2023-01-12 — — WO disclosed
WO-2022268051-A1 FUSED TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE 江苏恒瑞医药股份有限公司 2022-12-29 — — WO disclosed
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 — — US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 — — US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 — — EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 — — EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250243187-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 PTPN1 1570/4885NR1H2 449/4885NR1H3 380/4885
US-20240327434-A1 FUSED TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE KRAS, NRAS, HRAS PTPN1 1189/4885NR1H2 531/4885NR1H3 490/4885
US-20240390340-A1 PYRROLIDINE KRAS INHIBITORS KRAS, NRAS, HRAS PTPN1 847/4885NR1H2 2168/4885NR1H3 2407/4885
US-20230093249-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 PTPN1 1570/4885NR1H2 449/4885NR1H3 380/4885
US-11851422-B2 Anti-viral compounds EIF2AK2, ZC3HAV1, HAVCR2 PTPN1 1570/4885NR1H2 449/4885NR1H3 380/4885
US-20240018126-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 PTPN1 1570/4885NR1H2 449/4885NR1H3 380/4885
US-20240109871-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 PTPN1 1570/4885NR1H2 449/4885NR1H3 380/4885
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE PTPN1 2663/4885NR1H2 3381/4885NR1H3 3101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.